Literature DB >> 7946410

Fate of patients with residual tumour at the bronchial resection margin.

C Gebitekin1, N K Gupta, C M Satur, G Olgac, P G Martin, N R Saunders, D R Walker.   

Abstract

The presence of microscopic deposits of tumour cells at the bronchial resection margin (BRM) may adversely affect the prognosis of patients. Residual tumour cells were identified at the BRM in 40 (5.4%) of 735 patients who had been operated on for non-small cell lung carcinoma (NSCLC). The extent of disease was stage I in 7 (17.5%), stage II in 21 (52.5%), stage IIIa in 10 (25%) and stage IIIb in 2 (5%) patients. Malignant cells were found to have infiltrated the submucosal lymphatics in 5 (12.5%) cases and the peribronchial tissue in the remaining 35 (87.5%). Fifteen (37.5%) patients received adjuvant radiotherapy (RT). Recurrence of the disease was diagnosed in 29 (72.5%) patients after a median of 17 months (range 3-111). The recurrence was local in 17 (59%) and distant in 12 (41%). The 5-year overall actuarial survival rate was 21.6% and was not affected by RT (P = NS). Only patients with stage IIIa disease and a positive bronchial stump had a significantly reduced 5-year survival rate compared to those with a negative stump, 0% vs 17% (P < 0.001). Tumour cells at the resection margin did not affect the survival in this cohort except those with stage IIIa disease, and the addition of adjuvant RT did not significantly affect its recurrence in patients with NSCLC.

Entities:  

Mesh:

Year:  1994        PMID: 7946410     DOI: 10.1016/1010-7940(94)90025-6

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  9 in total

1.  Hand-held spectroscopic device for in vivo and intraoperative tumor detection: contrast enhancement, detection sensitivity, and tissue penetration.

Authors:  Aaron M Mohs; Michael C Mancini; Sunil Singhal; James M Provenzale; Brian Leyland-Jones; May D Wang; Shuming Nie
Journal:  Anal Chem       Date:  2010-10-06       Impact factor: 6.986

2.  Improving lung cancer outcomes by improving the quality of surgical care.

Authors:  Raymond U Osarogiagbon; Thomas A D'Amico
Journal:  Transl Lung Cancer Res       Date:  2015-08

3.  An integrated widefield imaging and spectroscopy system for contrast-enhanced, image-guided resection of tumors.

Authors:  Aaron M Mohs; Michael C Mancini; James M Provenzale; Corey F Saba; Karen K Cornell; Elizabeth W Howerth; Shuming Nie
Journal:  IEEE Trans Biomed Eng       Date:  2015-01-09       Impact factor: 4.538

4.  Label-free hyperspectral imaging and quantification methods for surgical margin assessment of tissue specimens of cancer patients.

Authors:  Baowei Fei; Martin T Halicek; Xu Wang; Hongzheng Zhang; James V Little; Kelly R Magliocca; Mihir Patel; Christopher C Griffith; Mark W El-Deiry; Amy Y Chen
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2017-07

Review 5.  Nanotechnology applications in surgical oncology.

Authors:  Sunil Singhal; Shuming Nie; May D Wang
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

6.  Prevalence, Prognostic Implications, and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer in the U.S. National Cancer Data Base.

Authors:  Raymond U Osarogiagbon; Chun Chieh Lin; Matthew P Smeltzer; Ahmedin Jemal
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

7.  Tumor margin assessment of surgical tissue specimen of cancer patients using label-free hyperspectral imaging.

Authors:  Baowei Fei; Guolan Lu; Xu Wang; Hongzheng Zhang; James V Little; Kelly R Magliocca; Amy Y Chen
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2017-02-14

8.  Label-free reflectance hyperspectral imaging for tumor margin assessment: a pilot study on surgical specimens of cancer patients.

Authors:  Baowei Fei; Guolan Lu; Xu Wang; Hongzheng Zhang; James V Little; Mihir R Patel; Christopher C Griffith; Mark W El-Diery; Amy Y Chen
Journal:  J Biomed Opt       Date:  2017-08       Impact factor: 3.170

9.  Postoperative radiotherapy for pathological stage IIIA-N2 non-small cell lung cancer with positive surgical margins.

Authors:  Meng Yuan; Yu Men; Jingjing Kang; Xin Sun; Maoyuan Zhao; Yongxing Bao; Xu Yang; Shuang Sun; Zeliang Ma; Jianyang Wang; Lei Deng; Wenqing Wang; Yirui Zhai; Wenyang Liu; Tao Zhang; Xin Wang; Nan Bi; Jima Lv; Jun Liang; Qinfu Feng; Dongfu Chen; Zefen Xiao; Zongmei Zhou; Luhua Wang; Zhouguang Hui
Journal:  Thorac Cancer       Date:  2020-11-27       Impact factor: 3.223

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.